[Pubmed] Rescue therapy in myasthenia gravis
Posté : 16 oct. 2025 12:00
Int Rev Neurobiol. 2025;183:113-132. doi: 10.1016/bs.irn.2025.04.018. Epub 2025 Oct 8.
ABSTRACT
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by fluctuating muscle weakness due to impaired neuromuscular transmission. Despite therapeutic advances, acute exacerbations and myasthenic crises remain significant challenges. This chapter offers an in-depth overview of rescue therapies for MG, detailing the mechanisms, efficacy, and safety of established treatments such as IVIG and PLEX, and discussing the potential of novel therapies like eculizumab and efgartigimod in acute MG management. We emphasize the importance of personalized treatment approaches tailored to factors such as antibody status, disease severity, and comorbidities. Strategies for monitoring treatment response and managing complications are also discussed. By synthesizing current evidence and expert recommendations, this chapter aims to equip clinicians with the knowledge needed to optimize rescue therapy in MG, ultimately improving outcomes during acute exacerbations and crises.
PMID:41101818 | DOI:10.1016/bs.irn.2025.04.018
Source: https://pubmed.ncbi.nlm.nih.gov/4110181 ... 22+67771e2